The exploratory analaysis for the efficacy and safety of Rikkunshito for appetite loss during the treatment with PEG-IFN and ribavirin

The exploratory analaysis for the efficacy and safety of Rikkunshito for appetite loss during the treatment with PEG-IFN and ribavirin - The analaysis for the efficacy and safety of Rikkunshito for appetite loss during the treatment with PEG-IFN and ribavirin

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003731

Enrollment

Registered

2010-06-10

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

Rikkunshito 7.5g per day 2 weeks Domperidone 30mg per day 2 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) The patients with chronic hepatitis C (2) During the treatment with PEG-IFN + Ribavirin (3)Appetite loss

Exclusion criteria

Exclusion criteria: (1)post gastrectomy (2)Use of other Kampo medicine (3)Gastrointestinal bleeding, ilues, perforation of gut

Design outcomes

Primary

Measure	Time frame
Appetite loss	—

Secondary

Measure	Time frame
QOL of gastrointestinal symptom Change of ghrelin and leptin body weight Depression	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026